Google
ANVS — ANNOVIS BIO INC (Healthcare >> Biotechnology)
ANVS FAQ
What is ANVS's ROE?
ANNOVIS BIO INC reports a Return on Equity (ROE) of -1,309.11%.
What is ANVS's dividend yield?
ANNOVIS BIO INC offers a dividend yield of 0.00%.
What is ANVS's Deepscope Quality Score?
Deepscope rates ANVS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANVS?
Deepscope's AI Timing Score for ANVS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANVS belong to?
ANNOVIS BIO INC is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.
|
USD 1.78
Price
-0.05
(-2.73%)
Day Change
|
|
|---|
ANVS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.78 |
| PBV / Sector |
24.90 / 4.91
|
| Earning Per Share | -0.94 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
2.61 M
GREAT
|
| Average 1W Daily Value |
1.75 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-13 11:13:07 |
| Symbol | ANVS |
| Name | ANNOVIS BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 42.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 77.85 / 9,034.83 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355
Phone: 484 875 3192
Website: https://www.annovisbio.com
Sector: Healthcare >> Biotechnology
Description: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
